• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600771.SS
Share

GuangYuYuan Chinese Herbal Medicine Co., Ltd. Stocks

CN¥ 15.32Last Updated 15.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 1.03B

CN¥ 15.32
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

GuangYuYuan Chinese Herbal Medicine Co., Ltd. specializes in the production and sale of traditional Chinese pharmaceutical goods. Their comprehensive range includes both classic and high-quality Chinese medicines, in addition to health-boosting wines. These remedies are available in diverse formats, such as pills, powders, tablets, hard capsules, granules, oral liquids, decoctions, and various wine preparations. The enterprise, which previously operated as Topsun Science And Technology Co Ltd., adopted its current name, GuangYuYuan Chinese Herbal Medicine Co., Ltd., in July 2013. Its primary operations are located in Xi'an, China.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, o

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 14:33

Where to Invest $1,000 Right Now: 4 Stocks to Consider in the Third Quarter

15.07.2026 13:49

Apple has found a startup that reduces the size of AI models. This could help it improve Siri

15.07.2026 11:45

HSBC has named Kaspi shares its top pick for July. Why does it expect them to rise by a third?

15.07.2026 11:26

PayPal Shares Surge: Fintech Giant Stripe Offers to Buy It — Reuters

15.07.2026 11:00

China's GDP growth has slowed to a three-year low. What can we expect from Beijing?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026